The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
This publication reviews the role of single-agent and dual immunotherapy for the treatment of metastatic non-small-cell lung cancer, recapping key insights from a scientific interchange & workshop.
EP: 1.Dr. Giaccone on Treatment Options in NSCLC
EP: 2.Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC
EP: 3.Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC
EP: 4.Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC
EP: 5.Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC
EP: 6.Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC
EP: 7.Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC
EP: 8.Dr. Garon on Immunotherapy Treatment Considerations in NSCLC
Now Viewing
EP: 9.The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Related Videos
Related Content
